LASSBio Chemical Library
It is not about size, it is about quality.
It is not just about hits, it is about how to lead your project.
WHO WE ARE
In the Medicinal Chemistry scene, LASSBio™ has been a pioneer player involved in the birth, growth and evolution of the Brazilian Medicinal Chemistry community. Considering all the responsibilities that this role brings, we are always engaged in evolve and adapt our process and philosophy to meet the challenges that the ever changing nature of the Drug Discovery process and its paradigms demand.
It is no secret that the contemporary iteration of the Drug Discovery paradigm rests on the exploration of large compound collections, also known as Chemical Libraries or Screening Libraries, aiming to identify promising ligands that are suitable for further optimization of their PK/PD profile, in the process known as hit-to-lead optimization, having as its final goal the discovery of a drug candidate.
​
How these Chemical Libraries are thought, planned and developed is going to make a huge difference in the outcome of the Drug Discovery programs that rely on those libraries to succeed. As it couldn't be any different, here at LASSBio™, we also have our own Chemical Library, a collection of nearly 2000 compounds, exclusively designed with drug-likeness, lead-likeness and pharmacological activity as the main priority, through the last 25 years of Drug Design expertise and excellence.
ABOUT OUR LIBRARY
-
Our Library is divided according to its innovation level. We have a public library, with approximately 1800 known, published compounds, designed and developed by our group. And there is our original library, with exclusive compounds, that are still under confidential terms, due to being current under development in house or with other partners;
-
The great majority of the compounds have shown some level of in vivo activity, indicating that they possess overall favorable bioavailability, suggesting an adequate pharmacokinetic profile;
-
Approximately half of our library is composed by N-acylhydrazone (NAH) derivatives. This feature can translate to a distinct advantage as this privileged scaffold is still less explored than others in the Drug Design context, despite many literature findings pointing to its applicability and potential in many therapeutic areas. This gap provides a huge opportunity for innovation and patentability.
DRUG-LIKENESS PROFILE
Molecular Weight versus cLogP distribution of the library's compounds
